Literature DB >> 6435554

Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences.

W Löscher, H Nau.   

Abstract

The transfer of the antiepileptic drug valproic acid (2-propyl-pentenoic acid) and one of its active metabolites, 2-en (2-propyl-2-pentenoic acid) from plasma to brain and liver were studied in mice at low dose levels (0.1, 0.3, 0.7, and 1.0 mmole/kg). The liver concentrations of 2-en were found to be lower than those of VPA: the liver/plasma ratios of 2-en for the four doses were 0.1, 0.2, 0.3 and 0.8, respectively; for VPA the corresponding liver/plasma ratios were 3, 2, 1.2 and 1.0, respectively. Following doses of 0.1-0.7 mmole/kg, plasma protein binding of 2-en (free fractions 2-7%) was much more extensive than of VPA (free fractions 40-45%). Also in the rat the liver/plasma concentration ratios of 2-en (0.3) were much below those of VPA (0.6). In mice, brain concentrations of 2-en were approximately 1/2 of corresponding plasma levels. Our results indicate that the transfer of 2-en into liver is limited by extensive protein binding of this compound in plasma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6435554

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  5 in total

1.  Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats.

Authors:  D Hönack; C Rundfeldt; W Löscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

2.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Delta 2-valproate biotransformation using human liver microsomal fractions.

Authors:  G Fabre; C Briot; E Marti; J P Montseny; M Bourrié; D Massé; Y Berger; J P Cano
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 4.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 5.  Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.

Authors:  W Löscher
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.